Quince Therapeutics (QNCX) Change in Account Payables (2018 - 2026)

Quince Therapeutics' Change in Account Payables history runs 9 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 26768.18% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $4.9 million (up 456.07% YoY), while the FY2025 annual figure was -$940000.0, down 201.4% from the prior year.
• Change in Account Payables for Q1 2026 stood at $5.9 million, up from -$1.2 million in the prior quarter.
• The five-year high for Change in Account Payables was $5.9 million in Q1 2026, with the low at -$3.5 million in Q2 2022.
• The 5-year median for Change in Account Payables is -$127000.0 (2023), against an average of -$19588.2.
• The sharpest annual moves came in 2024 and 2026: Change in Account Payables tumbled 1600.0% in 2024, then jumped 26768.18% in 2026.
• Quince Therapeutics' Change in Account Payables stood at -$614000.0 in 2022, then jumped by 79.32% to -$127000.0 in 2023, then soared by 1163.78% to $1.4 million in 2024, then slumped by 185.42% to -$1.2 million in 2025, then surged by 612.22% to $5.9 million in 2026.
• Business Quant data shows QNCX's Change in Account Payables at $5.9 million in Q1 2026, -$1.2 million in Q4 2025, and $1.6 million in Q3 2025.